BD Names Shawn Bevec as Senior Vice President of Investor Relations
Rhea-AI Summary
BD (NYSE: BDX) named Shawn Bevec senior vice president of investor relations, effective Jan. 20, 2026. Bevec will lead investor communications and report to interim CFO Vitor Roque until a new leader is appointed. He joins from Quest Diagnostics, where he served as vice president of investor relations, and previously worked as a sell‑side analyst at Deutsche Bank and Susquehanna International Group and in R&D roles at Pfizer and Johnson & Johnson. Bevec holds a B.S. in Chemistry from the University of Arizona and an MBA from NYU Stern.
Positive
- Experienced IR leader joining from Quest Diagnostics
- Sell‑side analyst background covering medical devices and health care
- Scientific foundation from R&D roles at Pfizer and Johnson & Johnson
- Effective Jan. 20, 2026
Negative
- Interim CFO oversight indicates finance leadership transition ongoing
- Reporting structure temporary until a new leader is appointed
News Market Reaction – BDX
In the Jan 14 session, BDX gained 2.93%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 05 | Trial progress update | Positive | +2.1% | Reported Phasix trial enrollment progress and first prophylactic use in Greece. |
| Dec 18 | R&D collaboration | Positive | -0.3% | Announced immune profiling collaboration with Penn using BD flow cytometry. |
| Dec 15 | Assay expansion | Positive | -1.9% | Disclosed new IVDR-certified VIASURE assays for the BD MAX System in Europe. |
| Dec 04 | Safety collaboration | Positive | +0.1% | Formed collaboration with ChemoGLO to expand hazardous drug testing solutions. |
| Dec 03 | Product launch | Positive | +1.6% | Launched new BD FACSDiscover A8 configurations for broader lab access. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent product and collaboration news has more often led to modest positive alignment, but there are instances where positive updates coincided with small declines.
Over the past few months, BD has focused on product innovation and clinical progress. In Dec 2025, it expanded BD FACSDiscover A8 configurations and announced a collaboration with ChemoGLO, with modest positive share reactions around +1.6% and +0.1%. Additional news included European IVDR-certified assays on BD MAX and a major immune-profiling collaboration with Penn. In Jan 2026, BD highlighted progress on the PREVENT trial and Phasix™ Mesh adoption, which saw a +2.06% move. Today’s investor-relations leadership appointment sits against this backdrop of steady strategic execution.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FRANKLIN LAKES, N.J., Jan. 14, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Shawn Bevec has been named senior vice president of investor relations, effective Jan. 20.
In this role, Bevec will lead all aspects of communicating the progress of BD's strategy to investors and the financial community, including the company's initiatives that drive shareholder value. He will report to Vitor Roque, the company's interim chief financial officer, until a new leader is appointed.
"As BD enters an exciting new chapter of growth, Shawn will be instrumental in articulating our strategy, performance and growth opportunities to the investor community – reinforcing BD's position as a leader in Medtech," said Roque. "Shawn's deep expertise in investor relations, equity research and the health care sector uniquely position him to lead this function as we advance our long–term growth plans and aim to deliver greater value for patients, customers and shareholders."
Bevec brings extensive experience in investor relations and equity research to BD. He joins the company from Quest Diagnostics, where he served as vice president of investor relations, leading investor communications, earnings-related activities and engagement with the capital markets. Prior to Quest Diagnostics, Bevec was a sell-side research analyst at Deutsche Bank and Susquehanna International Group, where he covered the health care services and medical devices sectors. Earlier in his career, Bevec held research and development roles at Pfizer and Johnson & Johnson, providing him with a strong scientific and operational foundation.
Bevec holds a Bachelor of Science in Chemistry from the University of
About BD
BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharmaceutical systems and interventional solutions. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 70,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X @BDandCo or Instagram @becton_dickinson.
Contacts: | |
Media | Investors |
Megan Dubrowski | Adam Reiffe Vice President, Investor Relations 201.847.6927 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-names-shawn-bevec-as-senior-vice-president-of-investor-relations-302660194.html
SOURCE BD (Becton, Dickinson and Company)